The Canada generic drug market size reached USD 10.4 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 19.7 Billion by 2033, exhibiting a growth rate (CAGR) of 7.3% during 2025-2033. The growing number of hospitals and clinics, favorable government initiatives, and the rising prevalence of chronic diseases represent some of the key factors driving the market.
Report Attribute
|
Key Statistics
|
---|---|
Base Year
|
2024
|
Forecast Years
|
2025-2033
|
Historical Years
|
2019-2024
|
Market Size in 2024
|
USD 10.4 Billion |
Market Forecast in 2033
|
USD 19.7 Billion |
Market Growth Rate 2025-2033 | 7.3% |
Generic drugs are medications created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use. They work in the same way and provide the same clinical benefits as the brand-name medicine. They meet the same high standards of quality and manufacturing and use active ingredients to offer the same benefits as the patent medicines. They can be oral, intravenous, intramuscular, nebulizer, and topical. They are highly cost-effective as the drug manufacturer does not have to duplicate the original clinical trials for effectiveness and safety. They are easily available and patients do not need to investigate far to find alternatives to popular non-generic medicines. As they are usually covered by insurance companies due to their low cost, the demand for generic drugs is rising in Canada.
At present, the increasing demand for generic drugs among the masses due to the patent expiry of various branded drugs in Canada represents one of the key factors supporting the growth of the market. Besides this, there is a rise in the demand for generic drugs as they are highly affordable on account of lower requirements for research and development (R&D) activities, physician visits, and marketing. This, along with the thriving pharmaceutical industry in Canada, is propelling the growth of the market. In addition, the growing awareness among individuals about the benefits of generic drugs is positively influencing the market. Moreover, governing agencies of Canada are promoting the usage of generic drugs through various mechanisms, such as tax incentives, subsidies, and market access arrangements. They are also organizing campaigns to create awareness among people about the benefits of generic drugs, which is contributing to the growth of the market. Apart from this, the wide availability of generic drugs through offline and online distribution channels is offering lucrative growth opportunities to industry investors in Canada. Additionally, the rising prevalence of chronic diseases, such as cancer, heart disease, stroke, diabetes, and arthritis, is strengthening the growth of the market. In line with this, the growing number of hospitals and clinics providing high-quality healthcare facilities to patients in Canada is offering a favorable market outlook.
The market report by IMARC Group provides extensive coverage of the performance of the generic drug market in Canada. The study provides in-depth information about the value and volume trends, COVID-19 impact, and market forecast from 2025-2033.
The report has also provided a comprehensive analysis of the competitive landscape in the Canada generic drug market. Competitive analysis such as market structure, market share by key players, player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided. Some of the companies covered include Apotex Inc., Mylan Pharmaceuticals ULC, Pharmascience Inc., Sandoz AG, Sun Pharma Industries Ltd., Teva Pharmaceutical Industries Limited, etc. Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Benefits for Stakeholders:
The Canada generic drug market was valued at USD 10.4 Billion in 2024.
We expect the Canada generic drug market to exhibit a CAGR of 7.3% during 2025-2033.
The high prevalence of numerous chronic diseases, such as diabetes, dyslipidemia, hypertension, etc., owing to the sedentary lifestyles, hectic work schedules, and changing dietary patterns of the consumers, is primarily driving the Canada generic drug market.
The sudden outbreak of the COVID-19 pandemic has led to the extensive R&D activities pertaining to the launch of generic drugs to combat the spread of the coronavirus infection across the nation.
Some of the major players in the Canada generic drug market include Apotex Inc., Mylan Pharmaceuticals ULC, Pharmascience Inc., Sandoz AG, Sun Pharma Industries Ltd., Teva Pharmaceutical Industries Limited, etc.